Icon

VYNDAMAX (nda212161)- (61MG)

TAFAMIDIS FOLDRX PHARMS
61MG
Yes No
2035-Aug-31 2024-May-03
None None
None No
VYNDAMAX is transthyretin stabilizers indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
0 2 0
Total Other Developers 11
Drugs with Suitability No
61MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.